MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock under atm,...
$45,712K
Proceeds from issuance of
common stock upon stock...
$5,756K
Proceeds from issuance of
common stock from...
$1,062K
Proceeds from pre-funded
warrant exercises
$6K
Net cash provided by
financing activities
$52,536K
Net (decrease)
increase in cash, cash...
-$70,804K
Canceled cashflow
$52,536K
Stock-based compensation
expense
$16,908K
Accounts payable
$4,240K
Other assets
-$1,361K
Amortization of operating
leases, right-of-use...
$529K
Amortization of debt discount
and issuance costs
$278K
Loss on fixed asset
disposal
-$135K
Other liabilities
$29K
Maturities and sales of
marketable securities
$97,831K
Net cash used in
operating activities
-$86,883K
Canceled cashflow
$23,480K
Net cash (used in)
provided by investing...
-$36,457K
Canceled cashflow
$97,831K
Net loss
-$97,352K
Accrued expenses and
other current...
-$10,200K
Prepaid expenses and
other current assets
$1,835K
Depreciation and
amortization expense
-$1,310K
Purchases of marketable
securities
$133,839K
Purchases of property and
equipment
$449K
Back
Back
Cash Flow
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)
source: myfinsight.com